Researchers have developed three new experimental compounds that activate two cellular receptors involved in blood sugar control, showing significant improvements in glucose tolerance and weight management in animal studies. According to Gram Research analysis, the most promising compound (DFL24102) reduced blood sugar spikes after eating and lowered triglycerides in mice without causing liver damage. However, these drugs remain in early laboratory and animal testing stages with no human trials yet, meaning they’re likely 10-20 years away from potential patient availability.
Scientists have developed three new experimental compounds that work on two different cellular receptors involved in blood sugar control and fat metabolism. According to Gram Research analysis, these dual-action drugs showed impressive results in laboratory and animal studies, improving glucose tolerance, reducing weight gain, and lowering triglycerides without causing liver damage. The compounds appear to work by activating receptors in the gut that trigger the release of hormones helping regulate blood sugar. While these findings are promising, the drugs are still in early development stages and haven’t been tested in humans yet, so it will be years before we know if they’ll become available treatments.
Key Statistics
A 2026 research article published in Biomedicine & Pharmacotherapy found that three novel dual GPR40/GPR120 agonists (DFL23914, DFL23915, and DFL24102) improved glucose tolerance in mice and reduced blood sugar spikes after eating, with DFL23915 and DFL24102 showing the most significant effects.
In fruit fly models of diet-induced metabolic dysfunction, chronic administration of the experimental compounds significantly improved locomotor performance, reduced body weight gain, and normalized both hyperglycemia and triglyceride accumulation without affecting survival rates.
Laboratory testing of the three novel compounds demonstrated they successfully stimulated glucagon-like peptide-1 (GLP-1) secretion and showed no hepatotoxicity, while exhibiting minimal systemic exposure consistent with a gut-restricted mechanism of action.
All three experimental compounds exhibited low-micromolar agonist activity at human GPR40 and GPR120 receptors, activating both calcium-dependent and beta-arrestin signaling pathways essential for metabolic regulation.
The Quick Take
- What they studied: Whether three new experimental drugs that activate two specific cellular receptors could help control blood sugar and fat metabolism better than current diabetes treatments.
- Who participated: Laboratory cell cultures and two animal models: fruit flies (Drosophila) and mice. No human participants were involved in this early-stage research.
- Key finding: All three compounds improved blood sugar control and reduced weight gain in animal models. Two of the drugs (DFL23915 and DFL24102) were particularly effective at lowering blood sugar spikes after eating, with no signs of liver damage.
- What it means for you: These results suggest a new approach to treating metabolic disorders might work, but it’s very early. These drugs haven’t been tested in humans yet, so it could be many years before they might become available treatments. Don’t expect these specific drugs to reach patients soon.
The Research Details
This was a laboratory and animal study testing three new experimental compounds. The researchers first tested how well the drugs activated two specific cellular receptors (GPR40 and GPR120) in human cells grown in dishes. They measured whether the drugs triggered the right cellular signals and whether they caused any damage to liver cells.
Next, they tested the drugs in fruit flies that had been fed a high-fat diet to mimic metabolic problems. They measured whether the flies moved better, gained less weight, and had better blood sugar and fat levels. Finally, they tested the most promising compounds in mice using a standard glucose tolerance test, which measures how well the body handles sugar after eating.
The researchers also studied how much of each drug actually entered the bloodstream, looking for evidence that the drugs worked mainly in the gut rather than throughout the whole body.
This research approach is important because it tests a new strategy for treating metabolic disorders. Instead of using just one drug target like current diabetes medications, these compounds activate two related receptors that work together. Testing in both fruit flies and mice helps researchers understand if the approach works across different organisms before considering human trials. The focus on gut-restricted activity is significant because it might mean fewer side effects from the drug circulating throughout the body.
This is early-stage research with solid methodology but important limitations. The study used established laboratory techniques and animal models commonly used in drug development. However, animal studies don’t always predict human results—what works in mice often doesn’t work the same way in people. The researchers didn’t specify exact sample sizes for all experiments, which makes it harder to evaluate statistical reliability. The work appears to be preliminary screening to identify which compounds are worth developing further, not a definitive proof that these drugs will work in humans.
What the Results Show
All three experimental compounds successfully activated both GPR40 and GPR120 receptors in human cells, triggering the cellular signals needed for blood sugar control. The compounds stimulated the release of glucagon-like peptide-1 (GLP-1), a hormone that helps regulate blood sugar—similar to how some current diabetes medications work.
In fruit flies fed a high-fat diet, chronic treatment with these compounds significantly improved movement ability, reduced weight gain, and normalized both high blood sugar and elevated triglycerides (blood fats). These benefits occurred in both adult flies and larvae without affecting survival rates.
In mice, oral administration of the drugs improved glucose tolerance during a standard test where animals are given sugar to eat. DFL23915 and DFL24102 showed particularly strong effects at reducing blood sugar spikes after eating. Importantly, laboratory tests showed no signs of liver toxicity from any of the three compounds.
The researchers found that DFL24102 showed the most balanced activation of both receptors, suggesting it might be the best candidate for further development. The drugs appeared to work primarily in the gut rather than throughout the bloodstream, which is advantageous because it may reduce side effects in other parts of the body. The compounds successfully stimulated GLP-1 secretion from intestinal cells, confirming they work through the expected biological pathway.
Current diabetes medications often target only one pathway for blood sugar control. This dual-receptor approach builds on existing knowledge that both GPR40 and GPR120 are involved in metabolic regulation. The study supports the emerging strategy of targeting multiple related receptors simultaneously, which may provide better metabolic control than single-target drugs. The gut-restricted mechanism aligns with recent interest in therapies that work locally in the intestines rather than systemically.
This research has several important limitations. First, no human participants were involved—results in animals don’t always translate to humans. Second, the study didn’t specify exact sample sizes for all experiments, making it difficult to assess statistical power. Third, the researchers only tested the compounds for a limited time period in animals, so long-term safety and effectiveness remain unknown. Fourth, the fruit fly and mouse models of metabolic dysfunction may not perfectly replicate human metabolic disorders. Finally, this is very early-stage research; the compounds would need extensive additional testing before any human trials could begin.
The Bottom Line
These findings are too preliminary to recommend any action for patients. This is basic research identifying promising drug candidates, not clinical evidence. People with metabolic disorders should continue following their doctor’s advice regarding current approved treatments. Moderate confidence in the research quality, but very low confidence in immediate practical application.
Researchers and pharmaceutical companies developing new metabolic disorder treatments should pay attention to these findings. People with type 2 diabetes, obesity, or metabolic syndrome might eventually benefit if these compounds advance through development, but that’s years away. Healthcare providers should not expect these specific drugs to become available soon. People should not seek out or attempt to obtain these experimental compounds.
Realistic expectations: If these compounds continue showing promise, they would need 5-10+ years of additional testing before potentially reaching human clinical trials. Even if human trials begin, it typically takes another 5-10 years for FDA approval. So realistically, these specific drugs might not be available to patients for 10-20 years, if at all. Many promising laboratory compounds never make it to market.
Frequently Asked Questions
Are these new diabetes drugs available to patients now?
No. These compounds are in very early laboratory and animal testing stages. They haven’t been tested in humans yet and likely won’t be available for 10-20 years, if at all. Many promising laboratory drugs never reach patients.
How do these experimental drugs work differently from current diabetes medications?
These compounds activate two related receptors simultaneously (GPR40 and GPR120) instead of targeting just one pathway. They work primarily in the gut to trigger hormones that regulate blood sugar, potentially causing fewer side effects than drugs circulating throughout the body.
What does it mean that the drugs work in the gut?
Gut-restricted activity means the drugs mainly affect the intestines rather than spreading throughout the bloodstream. This localized action may reduce unwanted side effects in other organs while still improving blood sugar control through intestinal hormone release.
Why were fruit flies and mice used instead of humans?
Animal models are used in early drug development to test basic safety and effectiveness before any human exposure. Fruit flies and mice have similar metabolic systems to humans but allow researchers to test many compounds quickly and ethically before human trials.
Should I ask my doctor about these drugs?
These are experimental compounds not available through any doctor. Continue using your current approved diabetes medications as prescribed. Discuss any interest in new treatments with your doctor at regular appointments, but these specific drugs aren’t an option yet.
Want to Apply This Research?
- Track fasting blood glucose levels weekly and post-meal glucose spikes (if using a glucose monitor) to establish your current baseline. This creates a reference point to compare against if similar medications become available in the future.
- While waiting for potential new treatments, use the app to log dietary choices that affect blood sugar—particularly high-fat meals and refined carbohydrates. This builds awareness of personal metabolic triggers and supports current treatment effectiveness.
- Maintain ongoing tracking of weight, energy levels, and blood sugar patterns. Set reminders to discuss metabolic health with your doctor at regular appointments. Use the app to note any changes in current medications or treatments, creating a comprehensive metabolic health record.
This article describes early-stage laboratory and animal research. These experimental compounds have not been tested in humans and are not available as treatments. This information is for educational purposes only and should not be interpreted as medical advice. People with metabolic disorders, diabetes, or obesity should continue following their healthcare provider’s treatment recommendations. Do not attempt to obtain or use these experimental compounds. Always consult with a qualified healthcare provider before making any changes to your treatment plan or lifestyle. The findings described here may not translate to human effectiveness or safety.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.